British Biotech Defends Patent In Gilead's Hep C Fight

Law360, London (March 23, 2021, 6:03 PM GMT) -- Biotech NuCana PLC is fighting a bid by Gilead Sciences to invalidate its patent relating to the treatment of cancer and viral diseases, saying the pharmaceutical giant's hepatitis C drugs infringe its intellectual property.

In its High Court defense and counterclaim, the Edinburgh-based NuCana pushed back against Gilead's lawsuit, which asserts that none of the elements stated within its patent create a new, patentable invention.

NuCana said in its March 17 filings that Gilead wasn't "entitled to the relief claimed or any relief," accusing the drugmaker of unlawfully profiting from its patented medical advance. The biotech asked the court for an...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!